GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » 5-Year RORE %

PetIQ (PETQ) 5-Year RORE % : -9.17% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is PetIQ 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. PetIQ's 5-Year RORE % for the quarter that ended in Dec. 2023 was -9.17%.

The industry rank for PetIQ's 5-Year RORE % or its related term are showing as below:

PETQ's 5-Year RORE % is ranked worse than
62.93% of 893 companies
in the Drug Manufacturers industry
Industry Median: 1.54 vs PETQ: -9.17

PetIQ 5-Year RORE % Historical Data

The historical data trend for PetIQ's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetIQ 5-Year RORE % Chart

PetIQ Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only - 82.70 5.98 27.02 -9.17

PetIQ Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.02 29.23 27.34 -10.79 -9.17

Competitive Comparison of PetIQ's 5-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, PetIQ's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetIQ's 5-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PetIQ's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where PetIQ's 5-Year RORE % falls into.



PetIQ 5-Year RORE % Calculation

PetIQ's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.06--0.49 )/( -6-0 )
=0.55/-6
=-9.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


PetIQ  (NAS:PETQ) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


PetIQ 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of PetIQ's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


PetIQ (PETQ) Business Description

Traded in Other Exchanges
Address
230 East Riverside Drive, Eagle, ID, USA, 83616
PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Products and Services segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, TruProfen, Betsy Farms, PetAction, Minties, Vera and Delightibles. The company generates maximum revenue from Products segment.
Executives
William J. Carter officer: EVP, GENERAL COUNSEL C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
John Paul Pearson officer: EVP, Services & Manufactured C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Robert Michael Herrman officer: General Counsel and Secretary 923 SOUTH BRIDGEWAY PLACE, EAGLE ID 83616
Michael A Smith officer: EVP - Products 923 S. BRIDGEWAY PLACE, C/O PETIQ, INC., EAGLE ID 83616
Kimberly Lefko director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Sheryl Oloughlin director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Scott Huff director 923. S. BRIDGEWAY PLACE, EAGLE ID 83616
Allan Hall director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Zvi Glasman officer: Chief Financial Officer C/O FOX FACTORY HOLDING CORP., 915 DISC DRIVE, SCOTTS VALLEY CA 95066
Kenneth C. Walker director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Susan Sholtis director C/O PETIQ, INC., 500 E. SHORE DRIVE, SUITE 120, EAGLE ID 83616
Mccord Christensen director, officer: Chief Executive Officer 500 EAST SHORE DRIVE, SUITE 120, EAGLE ID 83616
John Newland officer: Chief Financial Officer C/O TRUE SCIENCE LLC, 500 E. SHORE DRIVE SUITE 120, EAGLE ID 83616
Ronald Kennedy director, 10 percent owner 500 EAST SHORE DR, SUITE 120, EAGLE ID 83616
Ecp Helios Partners Iv, L.p. 10 percent owner 437 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022